The Liver Institute at Methodist Dallas
The Liver Institute at Methodist Dallas
Dallas, Texas, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 2 | 2026-09-30 | NCT07325526 | |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04849728 | |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndrome | Active, not recruiting | Phase 3 | 2026-05-27 | NCT04951219 |